Skip to main content

Advertisement

Table 3 Profiles of participants were categorized by smoking status for SLC6A3 , ANKK1/DRD2 , and CYP2A6 polymorphism genotypes

From: Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population

(A) Current smoker
Genotypes Number Age Age at which Duration of smoking
Male Female participant began smoking
SLC6A3 10r/10r 57 4 31.51 ± 11.72 19.33 ± 2.01 11.82 ± 11.12
10r/# or #/# 12 2 36.93 ± 13.36 19.36 ± 1.84 16.43 ± 13.12
   P-value 0.119 0.855 0.361
ANKK1/DRD2 A2/A2 25 2 34.05 ± 13.89 19.67 ± 2.15 13.98 ± 13.99
A2/A1 or A1/A1 44 4 31.65 ± 11.09 19.15 ± 1.87 11.95 ± 10.05
   P-value 0.435 0.523 0.965
CYP2A6 *1/*1 50 5 32.58 ± 11.79 19.27 ± 2.09 13.05 ± 11.90
*1/*4 or *4/*4 20 1 31.90 ± 13.16 19.14 ± 2.31 11.24 ± 10.73
   P-value 0.716 0.846 0.654
(B) Former smoker
Genotypes Number Age   
Male Female    
SLC6A3 10r/10r 15 1 48.69 ± 10.98   
10r/# or #/# 4 1 51.2 ± 6.98   
   P-value 0.901   
ANKK1/DRD2 A2/A2 6 0 50.667 ± 8.824   
A2/A1 or A1/A1 13 2 48.733 ± 10.760   
   P-value 0.697   
CYP2A6 *1/*1 16 2 49.44 ± 10.56   
*1/*4 or *4/*4 3 0 48.33 ± 8.02   
   P-value 0.840   
  1. #DAT alleles with less than 10 repeats. P-value; the Mann–Whitney U test was conducted for participant age and smoking history of each genotype.